Anebulo reports FY2023 net loss of $11.7M; cash $11.2M; FDA supports Phase 3

Anebulo Pharmaceuticals, Inc.

Net loss for FY2023 was $11.7M ($0.47 per share) vs $6.8M ($0.29) in FY2022.
Cash and cash equivalents at June 30, 2023 were $11.2 million.
Positive FDA Type B meeting supports advancing ANEB-001 to registrational studies; Phase 3 targeting H1 2024.
Dosing completed in Part C open-label extension of Phase 2 study; data readout expected Q4 2023.
Operating expenses in FY2023 were $11.8M, up from $6.8M, driven by R&D and G&A increases.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Anebulo Pharmaceuticals, Inc. reported three months ended June 30, 2023 results: net income Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, EPS $(0.10) per share.

Period: three months ended June 30, 2023
Net income: Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share
EPS: $(0.10) per share
Result: reported results

Exact text from the filing

Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.3 million, or $(0.10) per share, in the fourth quarter of fiscal 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Anebulo Pharmaceuticals, Inc. reported twelve months ended June 30, 2023 results: net income Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, EPS $(0.47) per share.

Period: twelve months ended June 30, 2023
Net income: Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share
EPS: $(0.47) per share
Result: reported results

Exact text from the filing

Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, compared with a net loss of $6.8 million, or $(0.29) per share, in fiscal year 2022.

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-033196

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.